<

HBM HEALTHCARE INVESTMENTS AG (FRA:CH001262) EQS-Adhoc: IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)

Transparency directive : regulatory news

22/03/2021 06:45

EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)

22-March-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


With Instil Bio (Nasdaq: TIL) and Connect Biopharma (Nasdaq: CNTB), two more private companies from the HBM Healthcare Investments portfolio successfully went public last Friday. 

Instil Bio raised USD 320 million in new capital by issuing 16 million shares at a price of USD 20.00 per share. On the first day of trading, the share price rose to USD 26.44 (+32.2%).

HBM Healthcare Investments has invested a total of USD 12.5 million in Instil Bio since June 2020. The investment was previously valued at USD 20.3 million based on the last financing round. A further USD 6 million was invested in the IPO. Following the IPO, HBM Healthcare Investments thus holds 2.2 million shares with a total value of USD 59.1 million.

Instil Bio is developing a cell therapy pipeline with autologous tumour-infiltrating lymphocytes (TIL) for the treatment of cancer. The lead TIL candidate, ITIL-168, is being developed for the treatment of advanced melanoma.

Connect Biopharma raised USD 191.3 million through the IPO by issuing 11.25 million American Depositary Shares (ADS) at a price of USD 17.00 per ADS. The shares closed at USD 18.49 (+8.8%) on the first day of trading.

HBM Healthcare Investments invested USD 10 million in Connect Biopharma in August 2020 and increased its stake by a further USD 5.1 million at the IPO. Following the IPO, HBM Healthcare Investments holds 1.2 million ADS worth USD 22.4 million.

Connect Biopharma develops therapies for the treatment of T-cell related inflammatory diseases. The company has a pipeline of four drug candidates. The two most advanced clinical-stage programmes, CBP-201 and CBP-307, are potentially differentiated product candidates against validated targets for the treatment of atopic dermatitis and ulcerative colitis and Crohn's disease.



End of ad hoc announcement
Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1177130

 
End of Announcement EQS Group News Service

1177130  22-March-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1177130&application_name=news&site_id=symex

HBM HEALTHCARE INVESTMENTS AG's latest news


18/03/2024 17:47
01/03/2024 17:47
16/02/2024 17:47
01/02/2024 17:47
22/01/2024 06:45
16/01/2024 17:47
03/01/2024 18:15
03/01/2024 18:13
18/12/2023 17:47
01/12/2023 18:18


Other stories

29/03/2024 03:31
29/03/2024 03:31
29/03/2024 01:30
28/03/2024 20:26
29/03/2024 03:05
28/03/2024 12:25
28/03/2024 11:24
28/03/2024 19:35
28/03/2024 21:00
28/03/2024 23:46
29/03/2024 01:58
28/03/2024 21:01
28/03/2024 17:47
28/03/2024 22:21
29/03/2024 03:31
28/03/2024 23:13
28/03/2024 09:59
28/03/2024 17:05
27/03/2024 15:52
27/03/2024 19:23
29/03/2024 03:00
27/03/2024 22:02
29/03/2024 03:31
29/03/2024 03:19
28/03/2024 21:58
29/03/2024 00:10
29/03/2024 00:17
29/03/2024 03:31
29/03/2024 03:31
28/03/2024 17:28
27/03/2024 21:46
29/03/2024 01:26
27/03/2024 13:40
28/03/2024 17:55
29/03/2024 00:01
28/03/2024 13:25
28/03/2024 19:18
28/03/2024 11:40